Our Expert Network

  1. The 9 Fastest-Growing Outsourcing Segments 11/7/2025

    Capacity isn’t the choke point—capability is; this piece ranks nine fast-growing outsourcing segments and shows sponsors how to win by locking in modality-proven partners early.

  2. Inside NeoVac's LNP Formulation Strategy: Challenges, Innovation, And What Comes Next 11/6/2025

    NeoVac CEO Jan Egberts, MD, discusses the science, regulation, and innovation shaping next-gen LNPs—and why true progress in mRNA therapeutics may depend more on understanding than on AI.

  3. Overcoming CMC Challenges In The Development Of Conjugated LNP Platforms For In Vivo CAR-T Therapy 11/4/2025

    Overcoming CMC hurdles is key to advancing conjugated LNP platforms for in vivo CAR-T therapy, enabling scalable, precise mRNA delivery to T cells while maintaining stability, potency, and regulatory compliance.

  4. Makary Talks Faster Drug Reviews, 'Continuous Trials,' DTC Ads 11/3/2025

    Part one of a two-part series on FDA Commissioner Martin Makary, M.D.'s comments at the Gailen Forum in New York City on October 30, 2025.

  5. Tackling Challenges In RNA Stability And Organ Targeting 10/28/2025

    RNA therapeutics are reshaping medicine, but instability and limited organ targeting still pose challenges. Discover how next-gen lipid nanoparticles and smart delivery systems are advancing RNA precision.

  6. Developing Exosome-Based RNA Therapeutics For CNS Regeneration 10/24/2025

    Inside the effort to use exosomes as natural nanocarriers that deliver RNA therapeutics safely across the blood–brain barrier to heal damaged neural tissue.

  7. Bridging RNA Innovation: A CEO's Guide To European Expansion 10/15/2025

    For RNA biotechs, Europe isn't just the next market — it's the ultimate test of strategy. Here's what CEOs need to know.

  8. Beyond LNPs: 4 Non-Viral Delivery Vehicles Expanding The Possibilities Of mRNA Therapeutics 10/6/2025

    While LNPs have emerged as the most promising non-viral delivery vehicles for mRNA therapeutics thus far, the field is rapidly expanding. To broaden mRNA’s applicability across a wider range of indications, companies are exploring innovative non-viral, non-LNP delivery vehicles, including polymers, engineered virus-like particles, and more.

  9. What You Should Know About USP's Bioassay Updates 10/2/2025

    The United States Pharmacopeia is overhauling general chapters to align them with current industry standards. One scientist on the project helps us unpack the changes.

  10. Contract Manufacturing Outsourcing Trends For Advanced Therapies In 2025 And Beyond 9/4/2025

    Contract manufacturing continues to emerge as the widely adopted model for bringing cell therapies, gene therapies, RNA therapeutics, and oligonucleotides to patients worldwide.